There are 2185 resources available
1965MO - Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Presenter: Vadim Koshkin
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
451MO - Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Presenter: Maria Angeles Vaz Salgado
Session: Mini oral session: CNS tumours
Resources:
Abstract
816MO - Two hematological precursors and their impact on hematological malignancies
Presenter: Nicholas Boddicker
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
1966MO - EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: Thomas Powles
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
452MO - Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
Presenter: Estela Pineda
Session: Mini oral session: CNS tumours
Resources:
Abstract
1967MO - Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Presenter: Matthew Galsky
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
453MO - A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
Presenter: Wenbin Li
Session: Mini oral session: CNS tumours
Resources:
Abstract
LBA50 - Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study
Presenter: Jonathan Spicer
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
847O - Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial
Presenter: Chaosu Hu
Session: Proffered paper session: Head and neck cancer
Resources:
Abstract
1817MO - Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial
Presenter: Jennifer Ligibel
Session: Mini oral session: Supportive and palliative care
Resources:
Abstract